Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that Dan Paterson, President and Chief Operating Officer, has been promoted to President and Chief Executive Officer . Brian Stuglik will retire from the CEO role and remain a member of the Board of Directors. These changes will be effective August 1, 2023, allowing for a smooth leadership transition.","Dan Paterson joined Verastem Oncology in 2011 and has served as Chief Operating Officer since 2014 and President since 2019
Company Information
Company
Verastem Oncology
Location
117 Kendrick Street, Suite 500
Needham, Massachusetts, United States
About
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition.
Fundz sees it the moment Verastem Oncology changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NeedhamBiotechnologyHealthcareHealth CareTherapeuticsBiopharma